Understanding the genetic complexity of puberty timing across the allele frequency spectrum.

Pubertal timing varies considerably and has been associated with a range of health outcomes in later life. To elucidate the underlying biological mechanisms, we performed multi-ancestry genetic analyses in ~800,000 women, identifying 1,080 independent signals associated with age at menarche. Collectively these loci explained 11% of the trait variance in an independent sample, with women at the top and bottom 1% of polygenic risk exhibiting a ~11 and ~14-fold higher risk of delayed and precocious pubertal development, respectively. These common variant analyses were supported by exome sequence analysis of ~220,000 women, identifying several genes, including rare loss of function variants in ZNF483 which abolished the impact of polygenic risk. Next, we implicated 660 genes in pubertal development using a combination of in silico variant-to-gene mapping approaches and integration with dynamic gene expression data from mouse embryonic GnRH neurons. This included an uncharacterized G-protein coupled receptor GPR83 , which we demonstrate amplifies signaling of MC3R , a key sensor of nutritional status. Finally, we identified several genes, including ovary-expressed genes involved in DNA damage response that co-localize with signals associated with menopause timing, leading us to hypothesize that the ovarian reserve might signal centrally to trigger puberty. Collectively these findings extend our understanding of the biological complexity of puberty timing and highlight body size dependent and independent mechanisms that potentially link reproductive timing to later life disease.
Competing Interests: Competing interests J.R.B.P. and E.J.G. are employed by Adrestia Therapeutics. D.J.T. is employed by Genomics PLC. D.L.C. and J.P.B. are employed by GSK. E.T. is employed by Pfizer. D.A.L. has received support from Roche Disgnostics and Medtroic Ltd for work unrelated to the research in this paper. T.D.S. is co-founder and stakeholder of Zoe Global Ltd. P.A.F. conducts research funded by Amgen, Novartis and Pfizer, he received Honoraria from Roche, Novartis and Pfizer. M.W.B. conducts research funded by Amgen, Novartis and Pfizer.